Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Coffee, Decaffeinated Coffee, and Tea Consumption Linked to Lower Diabetes Risk

By HospiMedica International staff writers
Posted on 22 Dec 2009
High intakes of coffee, decaffeinated coffee, and tea are linked to a reduced risk of Type 2 Diabetes Mellitus, according to a pooled review of studies.

Researchers at the George Institute for International Health (Sydney, Australia), the University of Glasgow (United Kingdom), and other institutions conducted a systematic review and meta-analysis investigating the association among coffee, decaffeinated coffee, and tea consumption with the risk of diabetes mellitus. More...
The meta-analysis included data obtained from 18 studies that reported on the association between coffee consumption and diabetes; six studies that reported estimates of the association between decaffeinated coffee and diabetes; and seven studies that reported on the association of tea.

The results of the pooled meta-analysis found that drinking coffee was inversely related to risk of diabetes (more coffee was linked to lower risk). After adjusting for potential confounders, every extra cup of coffee consumed in a day was linked to a 7% reduction in the excess risk of diabetes; drinking 3 to 4 cups per day was linked to a 25% lower risk than drinking none or up to two cups per day. In those studies that assessed decaffeinated coffee consumption, drinking more than 3 to 4 cups a day was linked to about one third lower risk of diabetes, compared to none. Drinking more than 3 to 4 cups of tea per day was linked to a one fifth lower risk of diabetes, compared to non-tea drinking. The authors suggested the effect of tea and coffee consumption on diabetes risk could be due to direct biological effects, since their apparent protective effect appears to be independent of potential confounding variables, and could partly be due to other compounds present in tea and coffee, such as magnesium, or antioxidants such as lignans or chlorogenic acids. The study was published in the December 14, 2009, issue of the Archives on Internal Medicine.

"If such beneficial effects were observed in interventional trials to be real, the implications for the millions of individuals who have diabetes mellitus, or who are at future risk of developing it, would be substantial,” concluded first author Rachel Huxley, M.D., of the George Institute, and colleagues. "It could also be envisaged that we will advise our patients most at risk for diabetes mellitus to increase their consumption of tea and coffee in addition to increasing their levels of physical activity and weight loss.”

Related Links:

George Institute for International Health
University of Glasgow



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammography System (Analog)
MAM VENUS
Digital Color Doppler Ultrasound System
MS22Plus
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.